GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover
By Bhanvi Satija and Yadarisa Shabong LONDON, June 9 (Reuters) - GSK has agreed to buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a major strategic shift under new CEO Luke Miels as the British company steps up its focus on